Source: BioPortfolio

Numerate: Numerate Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 22082017 Prices from USD $250

SummaryNumerate Inc Numerate is a biotechnology company that develops drug design platform. The company provides design of modulators of the ryanodine receptor 2 for the treatment of heart failure and atrial fibrillation. It designs agonists of the longcha...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Guido Lanza's photo - President & CEO of Numerate

President & CEO

Guido Lanza

CEO Approval Rating

77/100

Read more